An international team of scientists, led by UC San Diego researchers, has developed a new, multi-sensor tool that measures subtle changes in multiple sclerosis patients, allowing physicians to more frequently and more quickly respond to changes in symptoms or patient condition.
Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.
The naturally occurring molecule N-acetylcysteine (NAC) shows benefit in a clinical trial for multiple sclerosis.
Cardiologists at The Ohio State University Wexner Medical Center are the first in the U.S. to test a new type of ablation technology for patients suffering from atrial fibrillation, a common type of irregular heartbeat.
Like most people, John Gifford wasn’t looking forward to a colonoscopy when he arrived on the UCI Medical Center campus in Orange in 2018. The Riverside man, 65, was concerned about his family history of colorectal cancer and had dutifully scheduled an appointment with UCI Health gastroenterologist Dr. William Karnes. The exam turned out to be intriguing and enlightening – a far cry from what one expects during a colonoscopy, Gifford recalls with a laugh.
An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target.
Millions of people might eventually be spared the embarrassment and extreme isolation caused by wetting themselves, thanks to new research.
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).
John Theurer Cancer Center at Hackensack University Medical Center is the only site in New Jersey and one of just 17 in the country participating in a multicenter international Phase II study of an innovative personalized cancer vaccine being evaluated in combination with pembrolizumab immunotherapy in patients with melanoma that has been surgically removed but has a high risk of coming back. The hope is that the vaccine can prime a patient's immune system to be more responsive to immunotherapy and reduce the risk of cancer recurrence.
In experiments with human cells and mice, researchers at the Johns Hopkins Kimmel Cancer Center report evidence that combining the experimental cancer medication TAK228 (also called sapanisertib) with an existing anti-cancer drug called trametinib may be more effective than either drug alone in decreasing the growth of pediatric low-grade gliomas. These cancers are the most common childhood brain cancer, accounting for up to one-third of all cases. Low grade pediatric gliomas arise in brain cells (glia) that support and nourish neurons, and current standard chemotherapies with decades-old drugs, while generally effective in lengthening life, often carry side effects or are not tolerated. Approximately 50% of children treated with traditional therapy have their tumors regrow, underscoring the need for better, targeted treatments.
The University of Chicago Medicine Comer Children's Hospital was one of the sites for a landmark clinical trial that led to approval of the first oral immunotherapy treatment for peanut allergy in children and teens.
Loyola Medicine is among the first to conduct a clinical study using hypnotherapy to treat functional dyspepsia, a gastrointestinal disorder affecting approximately 10 percent of the population.
We know that stress can have a profound impact on health. But it’s rare to discover a health issue that is caused directly by stress. That’s exactly what one Michigan State University researcher and his team have found. Nathan Tykocki, an assistant professor of pharmacology and toxicology in the College of Osteopathic Medicine, set out to understand why children who seemingly have nothing wrong with them lose bladder function, a condition also known as stress-induced bladder dysfunction, or SIBD.
In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer.
In the early 90s, Dr. Jessie Casida was one of few nurses working on the first patient with a left ventricular assist device. The patient’s self-management responsibility was so complicated that it inspired him to create VADcare App.
The researchers behind the early-stage work, published in JCI Insight, are exploring whether kisspeptin can ultimately be used to treat men with common psychosexual disorders - sexual problems which are psychological in origin such as low libido.
In a new article published online ahead of print in Cancer Research, members of Moffitt’s Center of Excellence for Evolutionary Therapy present a case study of an adaptive treatment approach based on evolutionary principles in prostate cancer and suggest that these strategies may provide a path toward improved multidrug adaptive therapies.
Researchers have lifted fertility rates in older female mice with small doses of a metabolic compound that reverses the ageing process in eggs, offering hope for some women struggling to conceive.
Top-line data reported from international trial
An anti-cancer compound developed at the University of Michigan has shown “profound” activity in mouse models against two subtypes of leukemia — representing up to 40% of patients — a U-M research team reports in the Journal of Clinical Investigation.
A new study finds that one side effect of lupus could also make patients with the autoimmune condition more vulnerable to a skin infection, or spreading the infection to others.
In the future, robots could take blood samples, benefiting patients and healthcare workers alike. A Rutgers-led team has created a blood-sampling robot that performed as well or better than people, according to the first human clinical trial of an automated blood drawing and testing device.
Cancer-fighting compound fights obesity and diabetes: Eric Prossnitz, PhD, and his team reported that G-1, a cancer-fighting compound they discovered some years ago, reduces fat in obese mice. Although G-1 is currently in phase 1 clinical trials for cancer, Prossnitz and his team are planning preclinical studies to use G-1 to fight fat in obese people.
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck. APG-157 is made up of multiple compounds produced by plants, including curcumin. UCLA Jonsson Comprehensive Cancer Center researchers found that treatment with this botanical drug resulted in high concentrations of curcumin and its byproducts circulating in the blood and absorbed by tumor tissues within three hours after being taken orally.
Professor Yuval Shaked, head of the Technion Integrated Cancer Center, presents an outline for therapy that will prevent the development of cancer treatment resistance, with suggestions about how the information can be used clinically.
In a new paper published Feb. 4 in JAMA, Mayo Clinic researchers describe the benefits of in-home noninvasive ventilation therapy ― which includes a type referred to as bilevel positive airway pressure, or BiPAP ― for many patients with chronic obstructive pulmonary disease (COPD). The team identified a number of benefits, including reduced mortality, fewer hospital admissions, lower risk of intubation, improved shortness of breath, and fewer emergency department visits.
VICC is the first cancer center to enroll a patient in a clinical trial for this new technology developed by SQZ Biotechnologies of Watertown, Massachusetts. The investigational product is generated from the company’s technology that uses high-speed cell deformation to squeeze cells, creating a temporary disruption of their membranes and offering a window for the insertion of tumor antigens.
In a study in Nature Medicine, researchers describe how injection of neutralizing antibodies are associated with enhanced T cell responses that specifically recognize HIV.
In a study published in Cancer Cell, researchers reported new findings about the regulation of co-stimulatory molecules that could be used to activate cancer-killing immune cells – chimeric antigen receptor T-cells, or CAR-T – or decrease their activity.
UCLA researchers are part of an international team that reported the use of a stem cell gene therapy to treat nine people with the rare, inherited blood disease known as X-linked chronic granulomatous disease, or X-CGD. Six of those patients are now in remission and have stopped other treatments. Before now, people with X-CGD – which causes recurrent infections, prolonged hospitalizations for treatment, and a shortened lifespan – had to rely on bone marrow donations for a chance at remission.
Research by a University of Georgia psychologist shows that targeting one particular symptom of schizophrenia has a positive effect on other symptoms.
Researchers at the Johns Hopkins Kimmel Cancer Center in Baltimore, working with colleagues in the Netherlands, developed a blood test that can predict recurrence of gastric cancer in patients after surgery. A description of their test, which is still experimental, was published online Jan. 27 in the journal Nature Communications.
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient’s progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.
Ten years ago this week St. Jude Children’s Research Hospital and Washington University School of Medicine unveiled an ambitious collaboration to identify the genetic changes that lead to some of the world’s deadliest childhood cancers. The researchers proposed a three-year, $65 million project to sequence the complete normal and cancer genomes of more than 600 childhood cancer patients.
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announces plans to evaluate futibatinib (TAS-120), an inhibitor of the fibroblast growth factor receptor (FGFR).
A new drug that could make it easier for doctors to diagnose multiple sclerosis (MS) in its earlier stages has been approved for its first human trials by the U.S. Food and Drug Administration (FDA).
University Hospitals Seidman Cancer Center treated its first patient in a new clinical trial to validate the groundbreaking effects of the poliovirus on glioblastoma (GBM), a deadly Grade IV cancer of the brain. UH is the only Midwest site participating in this clinical trial, which was initiated at Duke Cancer Institute in Durham, NC. The original study, which ran from 2012-2017, was published in New England Journal of Medicine in July 2018 as well as highlighted on “60 Minutes” in 2015 and again in 2018. The study found that survival rates were significantly higher in glioblastoma patients who received an intratumoral infusion of a modified viral chimera combining the polio and rhinoviruses (PVSRIPO immunotherapy) compared to patients receiving standard treatment at the same institution.
The benefits of fetal surgery to repair spina bifida, a procedure pioneered at Vanderbilt University Medical Center (VUMC) in 1997, continue through school age, a National Institutes of Health (NIH) study reports today in the journal Pediatrics.
In women with uterine fibroids, the drug elagolix suppresses ovarian hormone production and prevents heavy menstrual bleeding
UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations.
Researchers have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types—the most commonly used viral vectors for in vivo gene therapy.
Both simple and advanced computed tomography (CT) were effective in accurately predicting which stroke patients would benefit from endovascular thrombectomy to remove a large cerebral clot, but together they were even better, reported researchers at UTHealth in Houston.
A University of Washington-led clinical trial involving more than 600 children in Kenya and Tanzania, in which community members were trained to deliver mental health treatment, showed improvement in participants’ trauma-related symptoms up to a year after receiving therapy.
The Cutaneous Oncology Program at the GW Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. The study, sponsored by Regeneron, will examine outcomes for patients treated with Libtayo® (cemiplimab) — an immunotherapy treatment — prior to surgery and radiation therapy.
Overweight and obese vitamin D-deficient children who took a relatively high dose of vitamin D every day for six months had lower blood pressure and improved insulin sensitivity than their peers who took a lower dose, according to the results of a new clinical trial.
Team members from eight Hackensack Meridian Health medical centers raised nearly $330,000 for Giving Heals, Meridian Health Foundation’s comprehensive fundraising campaign, which supports four important initiatives: strengthening oncology services, improving clinical outcomes, enhancing the patient experience and broadening clinical research and academic programs. To date, nearly $110 million has been raised toward a goal of $150 million to support Hackensack Meridian Health medical centers in Monmouth, Ocean and Middlesex counties.
In diseases like cancer, atherosclerosis, and sickle cell anemia, cathepsins promote their propagation. Drug trials to inhibit these enzymes have failed due to baffling side effects. Now a new study examines cathepsins in systems to remove some of the bafflement.
A variety of existing drugs for treating conditions such as diabetes, inflammation, alcohol abuse, and arthritis in dogs can also kill cancer cells in the lab, according to a study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right